Atıf İçin Kopyala
Karakan T., Coşkun M., Bilican G., Demir B., Karataş A., Ekmen N., ...Daha Fazla
JOURNAL OF CROHN'S AND COLITIS, cilt.18, sa.Supplement_1, ss.1536, 2024 (SCI-Expanded)
-
Yayın Türü:
Makale / Kısa Makale
-
Cilt numarası:
18
Sayı:
Supplement_1
-
Basım Tarihi:
2024
-
Doi Numarası:
10.1093/ecco-jcc/jjad212.0954
-
Dergi Adı:
JOURNAL OF CROHN'S AND COLITIS
-
Derginin Tarandığı İndeksler:
Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, MEDLINE
-
Sayfa Sayıları:
ss.1536
-
Gazi Üniversitesi Adresli:
Evet
Özet
Abstract
Background
The relationship between body fat composition and inflammatory bowel disease (IBD) progression, medical response, and prognosis is widely acknowledged. Visceral adipose tissue (VAT) has been shown to be profoundly responsible of most of the obesity-associated metabolic derangements, however it is also related to severity of inflammation. Although VAT can be estimated using computerized tomography, abdominal bioimpedance is a new and reliable technique without expense and radiation exposure. We investigated whether VAT is linked to the disease activity in severe IBD and the short-term response to biological therapies.
Methods
We prospectively evaluated 65 IBD patients, (n=26 with ulcerative colitis (UC) and n=39 with Crohn’s disease (CD) who had moderate-severe disease activity) at baseline before the initiation of biological therapy. We quantified VAT using abdominal bioimpedance (ViScan). VAT and other body fat metric measures (BMI, total and free fat mass, abdominal fat mass) were also analyzed. The response to biological agents was assessed by clinical (Mayo and CDAI) and endoscopical (mucosal healing) scores at 3 months.
Results
Out of the 65 patients, 22 individuals (33.8%) exhibited clinical and/or endoscopic response after 3 months. Among responders and non-responders, there was a comparable approximation of disease location (p=0.321) and behavior (p=0.239). Patients with CD had slightly lower levels of VAT, BMI, and free fat mass compared to those with UC. In non-responders with UC, VAT levels were lower than in responders, whereas in non-responders with CD, VAT levels were higher than in responders. No distinction was observed in the VAT response among other classes of biologics, including anti-TNF, ustekinumab, and vedolizumab.
Conclusion
In summary, VAT parameters using bioimpedance (ViScan) were found to be correlated with the disease activity and reliably identified IBD patients who responded well to various biological treatment in the short-term. Therefore, human fat indices might be novel biomarkers for disease severity and response to therapy.